Reply to: No effect of resistance-associated substitutions in patients with rare HCV subtypes following treatment with sofosbuvir-containing regimens by da Silva Filipe, Ana et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.jhep.2017.11.044
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
da Silva Filipe, A., Sreenu, V., Hughes, J., Aranday-Cortes, E., Irving, W. L., Foster, G. R., ... Thomson, E. C.
(2018). Reply to: No effect of resistance-associated substitutions in patients with rare HCV subtypes following
treatment with sofosbuvir-containing regimens. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2017.11.044
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Accepted Manuscript
Letter to the Editor
Reply to: No effect of resistance-associated substitutions in patients with rare
HCV subtypes following treatment with sofosbuvir-containing regimens
Ana da Silva Filipe, Vattipally Sreenu, Joseph Hughes, Elihu Aranday-Cortes,
William L Irving, Graham R. Foster, Kosh Agarwal, William Rosenberg,
Douglas Macdonald, Paul Richardson, Mark A. Aldersley, Martin Wiselka,
Andrew Ustianowski, John McLauchlan, Emma C. Thomson
PII: S0168-8278(18)30014-X
DOI: https://doi.org/10.1016/j.jhep.2017.11.044
Reference: JHEPAT 6821
To appear in: Journal of Hepatology
Received Date: 17 November 2017
Accepted Date: 22 November 2017
Please cite this article as: da Silva Filipe, A., Sreenu, V., Hughes, J., Aranday-Cortes, E., Irving, W.L., Foster, G.R.,
Agarwal, K., Rosenberg, W., Macdonald, D., Richardson, P., Aldersley, M.A., Wiselka, M., Ustianowski, A.,
McLauchlan, J., Thomson, E.C., Reply to: No effect of resistance-associated substitutions in patients with rare HCV
subtypes following treatment with sofosbuvir-containing regimens, Journal of Hepatology (2018), doi: https://
doi.org/10.1016/j.jhep.2017.11.044
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
Reply to: No effect of resistance-associated substitutions in patients with rare 
HCV subtypes following treatment with sofosbuvir-containing regimens 
Ana da Silva Filipe1, Vattipally Sreenu1, Joseph Hughes1, Elihu Aranday-Cortes1, William L 
Irving2, Graham R. Foster3, Kosh Agarwal4, William Rosenberg5, Douglas Macdonald5, Paul 
Richardson6, Mark A. Aldersley7, Martin Wiselka8, Andrew Ustianowski9, John McLauchlan1, 
Emma C. Thomson1 
1. MRC-University of Glasgow Centre for Virus Research, Glasgow, UK. 
 
2. Gastrointestinal and Liver Disorders Theme, NIHR Nottingham Biomedical Research 
Centre at  the Nottingham University Hospitals NHS Trust and the University of 
Nottingham, UK. 
3. Blizard Institute, Queen Mary University of London, London, UK. 
 
4. Institute of Liver Studies, King's College Hospital Foundation Trust, London UK. 
 
5. Institute of Liver and Digestive Health, University College of London, London, United 
Kingdom. 
6. Royal Liverpool University NHS Trust, Liverpool, UK. 
 
7. Liver Unit, St James’s University Hospital, Leeds, UK. 
 
8. Infectious Diseases Unit, University Hospitals Leicester NHS Trust, Leicester, UK. 
 
9. Infectious Diseases, North Manchester General Hospital, Manchester, UK. 
 
Financial Support: This work was supported by grants from the Medical Research 
Foundation to HCV Research UK (C0365) and the UK Medical Research Council (MRC) to 
the STOP-HCV consortium (MR/K01532X/1). AS, VS, JH, EAC, JM and ECT were also 
supported by the MRC (MC.UU.12014/1) and ECT was funded by the Wellcome Trust 
(102789/Z/13/Z). We are also grateful to Gilead Sciences and Bristol Myers Squibb for 
financial support. 
Correspondence: Prof J McLauchlan, MRC-University of Glasgow Centre for Virus 
Research, Sir Michael Stoker Building, Garscube Campus, Glasgow G61 1QH, UK; E-mail,  
john.mclauchlan@glasgow.ac.uk; Tel no. +44 141 330 4028. 
  
Conflict of Interest: The authors disclose the following conflicts: WLI has received 
speaker and consultancy fees from Roche Products, Janssen Cilag and Novartis, 
educational grants from Boehringer Ingelheim, MSD and Gilead Sciences, and research 
grant support from GlaxoSmithKline, Pfizer, Gilead Sciences and Janssen Cilag; GRF has 
received research grants from Roche, Gilead Sciences, Springbank, and received speaker 
and consultancy fees from AbbVie, Gilead Sciences, MSD, GSK and Janssen 
Pharmaceuticals; KA has received speaker and consultancy fees from AbbVie, Achillion, 
Astellas, BMS, Gilead Sciences, GSK, Janssen, MSD, Novartis; WR is among the inventors 
and patent holders for the ELF® Test and receives consultancy fees from Siemens; MAA 
has been an advisory board member and in receipt of educational grants from Gilead 
Sciences; AU has received speaker fees and advisory board fees from Gilead Sciences, 
ViiV, Abbvie, MSD, Janssen and BMS; JM has received speaker and consultancy fees from 
Abbvie, Gilead Sciences and BMS. The remaining authors have no conflicts to declare. 
Author Contributions: The study was designed and led by AS, JM and ECT. EAC, VS and 
JH formed NGS and host genetic analysis. WLI collated and provided the clinical data from 
HCV Research UK. GRF, KA, WR, DM, PR, MAA, MW and AU consented the patients, 
provided clinical data and provided samples. All authors contributed to and commented on 
the drafting of the final manuscript. 
  
To the Editor: 
 
We thank Zeuzem et al for their response to our recently published findings (1, 2). Their 
data provide a valuable addition to reports describing virological outcomes for patients 
infected with “rare” subtypes who have received sofosbuvir (SOF)-based therapy but have 
not been well represented in previous large-scale clinical trials. We agree with the authors 
that assessing treatment outcome in cohorts infected with poorly characterized or 
uncharacterized subtypes would ideally be determined from patients who have achieved 
both SVR and treatment relapse. However, well-defined cohorts do not exist in most low- 
and middle-income countries (LMICs) where such subtypes are typically found, and 
consequently the necessary evidence base has been lacking. 
We wish to comment further on the implications for treatment of patients in LMICs as part 
of the WHO global elimination plan. Recently, we published a study illustrating the lack of 
HCV sequence data in LMICs, particularly those in Africa as well as South and Central 
America (3). We agree that a SVR rate of 100% in 8 gt4r-infected patients treated with 
SOF/VEL±VOX is reassuring. However, the additional finding of SOF/LDV treatment failure 
in 2/4 patients with gt4r in Zeuzem et al’s larger analysis (1) is concerning although the 
authors did not give details of the disease status of these patients. In our study, all EAP 
patients had cirrhosis, which may well have influenced response to therapy. The apparent 
lower response of gt4r to SOF/LDV is worth highlighting for countries planning to use 
generic versions of these DAAs as treatment for gt4 infection where a significant proportion 
of patients are possibly infected with the gt4r subtype. Although gt4r is uncommon in 
Europe and the USA, it is not a rare genotype in Central African countries including the 
Democratic Republic of the Congo, the Republic of Congo, the Central African Republic, 
Burundi, and Gabon. It will be important for these countries to consider the potential 
advantage of using SOF/VEL-based treatment versus SOF/LDV to achieve high rates of 
HCV clearance. 
Finally, the large dataset provided by Zeuzem et al substantially increases the available 
data for DAA target genes in subtypes that are rare in high income countries (HICs). 
  
However, there remains a question as to whether the full extent of RAS polymorphisms in 
such subtypes should be considered as fully documented. Regarding gt1l, also associated 
with lower SVR rates in our study, we combined the sequence data for gt1l isolates across 
the HCV NS5A coding region between residues 24-32 where RAS typically occur from 
Zeuzem et al, our publication (Filipe et al) and available Genbank sequences. Our analysis 
shows that methionine is dominant at positions 28 and 31 (11/12 sequences). However, 
position 30 is polymorphic in gt1l (Q, n=7; R, n=5). In the common gt1 subtypes, gt1a 
and gt1b, position 30 does not show such variability; for gt1a, Q is encoded in 96% of 
sequences (4801/4983) and for gt1b, R is encoded in 92% of sequences (4328/4705) 
(McLauchlan, unpublished). The motif consisting of M28R30M31 is found not only in gt1l but 
also gt4r. The gt1l-infected patients reported by Zeuzem et al who had this motif received 
VEL and not LDV, which was the prescribed NS5A inhibitor in our EAP cohort. We note that 
one of the gt4r-infected patients in the Zeuzem et al study with the M28R30M31 motif did 
receive LDV and relapse occurred, the second patient who received LDV had a V28R30M31 
motif. All other gt4r-infected patients who achieved SVR received SOF/VEL±VOX. In the 
absence of relevant in vitro subgenomic replicons to test gt1l, we agree with Zeuzem et al 
that patients receiving SOF-based regimens for gt4r should be treated with VEL but this 
recommendation could be extended to geographic regions where gt1l may circulate to 
mitigate against possible resistance with strains containing the V/M28R30M31 motif. 
In summary, the available, modest data suggest that NS5A polymorphisms, which may 
impact treatment response are common in HCV strains from certain African genotypes. 
The impact of these polymorphisms appears to be minimal in patients receiving SOF/VEL- 
based regimens but there are concerns about the efficacy of LDV in these isolates. Further 
studies examining the effectiveness of current therapies in larger numbers of patients will 
be required to identify the optimum regimen for these potentially resistant subtypes. 
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